The charge of AAPM Task Group 113 is to provide guidance for the physics aspects of clinical trials to minimize variability in planning and dose delivery for external beam trials involving photons and electrons. Several studies have demonstrated the importance of protocol compliance on patient outcome. Minimizing variability for treatments at different centers improves the quality and efficiency of clinical trials.
| ABOUT TH IS E XECUTIVE SUMMARY
The full report of AAPM Task Group 113 on Guidance for the Physics Aspects of Clinical Trials is available at the AAPM Reports website. This executive summary provides an overview of the major headings of the full report. In addition, details were retained in this report to highlight a few areas where there has been an evolution in clinical trials. Appendices A-D include all of the TG113 recommendations with the reference information contained in the full report.
| INTRODUCTION AND CHARGE OF THE REPORT
There is growing evidence [1] [2] [3] [4] [5] on the need for standardization of treatment planning and delivery methods to ensure quality in clinical trials to help support the investigation of new safe and effective treatments and/or assessment methods in multi-institutional settings.
Such standardization will improve the consistency of the radiotherapy received by patients and the radiotherapy data submitted for a given clinical trial. These data are required to validate that all patients in each arm of a given study received the therapy as intended. Violating this assumption can jeopardize the validity of the outcomes reported by the trial group.
A related consideration that affects overall quality is the ability of those participating in clinical trials to create plans as part of their standard clinical flow that are both compliant with protocol specifications and optimal. The importance of compliance in trials and the impact on detecting changes in outcome have been demonstrated in a number of trials, [1] [2] [3] [4] 6 such as TROG 02.02 on advanced head and neck cancer (Fig. 1) , and in meta-analyses of other trials. When designing a trial, the planning guidelines are set to be able to answer
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
the clinical trial questions. However, there may be variation in planning methods, and a planner may not know when a better (such as improved target coverage with reduced dose to normal tissues) plan is reasonably achievable without real-time feedback during the planning process. Knowledge-based planning, where the achievable dosevolume metrics from previous patients can used to predict each new patient's DVH, was shown to retrospectively identify plans which were clinically acceptable but suboptimal in the context of the clinical trial. 7 For example, plan quality was analyzed for patients treated on RTOG 0126 exploring the relationship between plan quality and rectal toxicity. Suboptimal plans were identified by comparing predictions for target and organ-at-risk doses to those that were submitted as part of a trial for 219 IMRT patients. The library was created from plans which were defined as the best from the protocol based on a risk evaluation. This work highlights the challenge of using a series of DVH points alone as the primary guidance to create a treatment plan.
There is a richness of information available when comparing a new plan against a library of plans that have been previously determined to be optimal and protocol compliant. Improved planning tools such as those with knowledge-based planning have been needed for some The charge of AAPM TG 113 is to:
(1) recommend physics practices for clinical trials involving external photon and electron beam radiation therapy that ensure minimum standards for data quality in clinical trials.
(2) identify opportunities to improve consistency in each part of the planning and delivery process. AAPM task group reports are relevant to the work of TG 113. Figure 2 shows an overview of the major areas involved once a patient is enrolled in a clinical trial. For organs which will be evaluated with dose-volume histograms (DVHs), the protocol should specify how much of the organ must be any additional limits to doses to organs outside the treatment field. 15 A final critical concern is that some systems ignore the volume of an organ outside the dose calculation grid when reporting dose-volume parameters. For such systems, the dose-grid should cover the entire organ of interest so that derived dose-volume parameters used for treatment planning represent the entire organ.
Additional details and recommendations regarding segmentation are found in the full report.
| IMAGE REGISTRATION
Clinical studies that require multiple image datasets need to use image registration software. When multiple image modalities are used for treatment planning, the protocol designers should consider providing specific recommendations for internal or external landmarks that can validate the adequacy of the registration for treatment planning.
If the accuracy of the image registration for each patient affects the quality of the trial (such as in defining the target volume), the protocol designers and QA centers should require credentialing of the image registration software by using phantoms of known geometry and should follow the guidance of AAPM TG 132. 16 The physician directive should specify the goals of the image registration, the method and what anatomical region should be emphasized in the registration. 16 With respect to how image registration is used at the treatment unit, the trials designers should determine if it is necessary to distinguish between applications for target and normal tissue definition compared with daily online treatment guidance. Image registration considerations, which are described in the full report, may also differ if there is a midcourse plan adaptation and dose accumulation methods are utilized. 17 
| PATIENT AND TARGET POSITIONING
Patient and target positioning is affected by immobilization and the frequency and type of image guidance used at the treatment unit.
The margins for treatment planning are affected, as well as the achievable accuracy of image registration using multimodality imaging scans which are used to design and assess patient treatments, especially dose-response studies for clinical trials.
In the context of clinical trials, the type of recommended immobilization described and/or required in a particular trial depends on QA core functions and institutional preparation a. For credentialing, explicitly state which structures must be delineated by a physician rather than other personnel. Motion assessment and management a. Confirm that the motion assessment and management guidance specified in the protocol is followed whenever the range of motion meets published guidance limits.
b. Ensure that the contoured IGTV is reasonable considering the measured motion for a given protocol patient. ii. When needed for a study, image format should be DICOM or DICOM RT (as appropriate) for CT, MR, PET, portal, simulator, and DRR images.
iii. When needed for a study, structure set, plan and dose files should be in DICOM RT format.
iv. Supplemental data that needs to be submitted to QA centers should be able to be electronically submitted. e. Determine when re-credentialing is necessary.
f. Provide appropriate benchmark phantoms for each trial that requires them, as resources permit.Existing phantoms should be assessed for suitability before new ones are made.
g. Determine benchmark acceptability based on reasonable clinical practice for the radiation treatment convolved with the 90% confidence limit of the dose measurements by the QA center.
h. Make information available to team members at an institution to determine eligibility for a given trial based on past credentialing efforts. e. Create the appropriate software to allow automatic anonymization with coded ID labels of patients and plans.
f. Develop and make available a straightforward export of information to QA centers g. Make treatment planning systems IHE-RO compliant h. Enable tools or scripts that can be shared and then used at the local institution to assess protocol compliance are invaluable.
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